Case Report: Targeted Therapy with Anlotinib for a Rare Case of Spinal Cord Glioblastoma with FGFR3 Mutation

Primary spinal cord glioblastoma (PSC GBM) is a rare disease with limited treatment options. Here, we describe a case of PSC GBM treated with anlotinib in this report. Molecular characterization confirmed the presence of the MGMT promoter unmethylated, IDH wild type, FGFR3 p.S249C and p53 p.V73fs mu...

Full description

Saved in:
Bibliographic Details
Published inOncoTargets and therapy Vol. 15; pp. 771 - 776
Main Authors Liu, Ruiqiong, Wei, Wei, Hou, Huaying, Cong, Ping, Zhou, Yong, Yu, Xiaoming
Format Journal Article
LanguageEnglish
Published Macclesfield Dove Medical Press Limited 31.07.2022
Taylor & Francis Ltd
Dove
Subjects
Angiogenesis
Brain cancer
c-Kit protein
Cancer
Cancer therapies
Care and treatment
Case Report
Case studies
Chemotherapy
Fibroblast growth factor receptor 1
Fibroblast growth factor receptors
Genetic aspects
Glioblastoma
Glioblastoma multiforme
Irinotecan
Kinases
Ligands
Lung cancer
Magnetic resonance imaging
Medical prognosis
Mutation
Patients
Precision medicine
Protein-tyrosine kinase
Proteins
Radiation therapy
Remission
Spinal cord
Surgery
Tumor proteins
Tumors
Tyrosine
Online AccessGet full text

Cover

More Information
Summary:Primary spinal cord glioblastoma (PSC GBM) is a rare disease with limited treatment options. Here, we describe a case of PSC GBM treated with anlotinib in this report. Molecular characterization confirmed the presence of the MGMT promoter unmethylated, IDH wild type, FGFR3 p.S249C and p53 p.V73fs mutations in the patient. Anlotinib is a multitarget tyrosine kinase inhibitor that target VEGFR2/3, FGFR1-4, PDGFR[alpha]/[beta], and c-kit. After a partial resection of the tumor at the extramedullary invasion site, the patient was administered anlotinib 12 mg p.o. once every day (days 1-14, 21-day cycle) in combination with irinotecan chemotherapy (days 1 and 8, 21-day cycle). The patient exhibited significant symptom remission and partial response and was maintained for more than 10 months of follow-up. This case study showed that FGFR3 S249C may be a new marker for the treatment of PSC GBM with anlotinib. This case is also another strong support for molecular diagnosis and precision medicine. Keywords: spinal cord glioblastoma, FGFR3 mutation, anlotinib, targeted therapy, precision medicine
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S362185